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The COVID-19 pandemic is affecting every aspect of medical care delivery, with projections indicating an 
escalating and indefinite impact upon our daily lives1. Clinical oncology research participants are a 
particularly vulnerable population at this time, due to both their underlying condition and increasing 
uncertainty about the conduct of clinical trials during a global pandemic.  
Robust protections for clinical trial participants are well established in the form of clinical trial design 
and oversight, supported by caring and dedicated clinical and research staff. However, several 
considerations become increasingly important in the current situation, and researchers and clinicians 
treating patients enrolled in research must weigh these carefully.  
While we fully recognize the dynamic nature of the COVID-19 pandemic and its constant evolution in 
degree and scope2, as the medical ethics editorial team for The Oncologist, we would like to take this 
opportunity to discuss three clinical research ethics considerations that are critical for our cancer 
research community.  
1: Non-abandonment 
Non-abandonment is typically a consideration for clinical care rather than clinical research. However, 
patients on experimental oncology protocols with palliative or curative intent have a strong interest in 
remaining on trial. Thus, while clinical trial researchers are not classically recognized as having fiduciary 
duties with regard to research participants, the complex intersection of care, therapies, and 
experimental interventions inherent to clinical oncology research requires a more nuanced 
understanding of the overlap between research and clinical obligations. 
Despite the profound disruption of a global pandemic to daily clinical duties, tens of thousands of 
patients with cancer will continue to depend upon their providers to care for them, address their 
concerns, and direct therapeutics appropriately. For multiple reasons, aspects of this care will be altered 
in form and schedule. But every effort will be necessary to maintain and continue cancer-directed 
experimental therapies for patients with imminently life-limiting malignancies, whether they are 
surgical, radiation-based, and/or drug-based. Creative delivery systems such as tele-health, home 
infusions, remote laboratories, utilization of satellite facilities, and others will be critical.  
In addition, we need to be mindful that patients with cancer may well be some of those at the highest 
risk of poorer outcomes if they are infected with COVID-19. In China,  overall case fatality for those 
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without comorbidities was 0.9%, but was 6% for those with cancer3. WHO data are similar: the 
unadjusted fatality rate for those with no co-morbidities was 1.4% but 7.6% for those with cancer4. In a 
small study of 2007 hospitalized patients in China, cancer patients’ fatalities were significantly higher 
(39% vs 8%.)5   
We must balance this information with the need to provide patients with the cancer-directed 
interventions upon which they depend. If projected workforce shortages due to infections and familial 
obligations strain the clinical research staff as anticipated, it is likely that role evolution will occur, with 
cancer providers and researchers distributed across other roles within the delivery team.  
The central message should be that COVID-19 will impact the way clinical and research teams interact 
with research participants, but that our overarching commitment to be available, in contact, and 
providing experimental and therapeutic interventions in the best way possible should persist. Available 
and trusted resources for COVID-19 related caretaking should be disseminated broadly6. 
2: Flattening the curve 
One of the clear messages from the CDC indicates that the most effective way to slow the COVID-19 
pandemic and ultimately save lives is to “flatten the curve” of new infections7, spreading them across a 
larger time-continuum such that limited resources (e.g. hospital beds, ventilators, and clinicians) are less 
strained at any given time point.  As we all know, oncology trials are resource-intensive, and approved 
protocols frequently require significant in-person contact between participants and research and clinical 
staff.  That said, it is critical that we follow CDC recommendations for screening patients and isolating 
any with fevers/symptoms, postponing non-essential in-person visits, cancelling those solely for data 
collection/research, and arranging for telemedicine interactions as much as possible. These steps are 
directed towards the dual goals of protecting both our clinical workforce and our often-
immunocompromised participant population.  Since availability of providers to care for patients is 
crucial, all efforts must be made to increase supply of personal protective equipment so that exposed 
providers will be protected and continue to care for their patients.  
Protocol deviation is an important consideration for both research ethics and compliance, and the 
National Institutes of Health has recently released several helpful notices regarding federally-funded 
human subject research trials during the COVID-19 pandemic. These include encouraging investigators, 
together with their IRBs, to consider “limiting study visits to those needed for participant safety or 
coincident with clinical care” as well as conducting visits virtually8. FDA has issued similar guidance9. 
Every effort to document the nature, timing, and reason for any protocol deviations will be critical to 
ensure that regulatory and funding oversight can be updated once we are out of the current crisis. 
We must also be prepared to honor research participants’ right to stop their participation in any clinical 
trial, for any reason, including if they judge that the extra visits and procedures are too risky in this 
environment.  
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3: Emotional support  
The psychosocial impact of this pandemic remains unclear but will undoubtedly be profound10. Patients 
with cancer are already psychologically strained and are generally insufficiently screened and treated for 
related mental health concerns. In addition, those involved in clinical research have unique issues and 
perspectives related to their dual roles as patients and subjects11. Psycho-oncology caretakers and 
resources will be particularly critical during this time period and, where possible, may be provided 
remotely through online or phone support.  
Lastly, we would be bereft to ignore the psychosocial impact of the pandemic on our research teams, 
who may be isolated from their typical emotional support resources. Enabling close (virtual or phone) 
contact with the research team to air concerns, share best practices, and allow for continued 
community building is also vital12. 
Conclusion 
The COVID-19 pandemic is progressing with relentless speed and will further test the clinical and 
research infrastructure for all of us13. Patients with cancer enrolled in clinical trials remain intensely 
vulnerable to their underlying condition, infection with COVID-19, and to the stressors impacting health 
care delivery in general. Clinicians and researchers alike are behooved to consider how best to protect 
participants’ health and interests, and to support their collective well-being even during our most 
challenging moments. We know that we, as a cancer research community, are up to the task.  
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